# A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

> **NCT00328497** · PHASE2 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Carcinoid Tumor

## Interventions

- **DRUG:** Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

## Key facts

- **NCT ID:** NCT00328497
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-12
- **Final completion:** 2009-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2010-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328497, "A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00328497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*